The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the most important target for the design of novel therapies for COVID-19. The development of antibodies that can target this specific area can be done in vivo, which is a time-consuming in vitro process or which can take advantage of the flexibility of visualization technologies such as pH age visualization. Anti-CoV-RBD antibody was developed by pHa to visualize the extensive library of COVID-19 (LiAb-SFCOVID-19 ™) antibodies against SARS-CoV-2 RBD. Whereas generation of antibodies based on pH age does not require animal immunization or the use of immunogenic antigens, only small RBD proteins are used to isolate specific RBD ligands from the LiAb-SFCOVID-19 TM library. Furthermore, since the library is composed of immune libraries from COVID-19 patients, it possesses the largest and most important biological antibodies with important neutralizing activities.
Therefore, this specific antibody is a fully human immunoglobulin in IgG format. The ELISA (Enzyme-linked immunosorbent assay) test was used to test and verify its affinity for recombinantly expressed RBD. In addition, the neutralizing activity was tested by the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), which is designed to rapidly assess the neutralization potential of new antibodies without using natural viral particles.
Finally, IgG antibodies are expressed in the XtenCHO ™ high throughput mammalian transient system, exhibit very stable stability and consistently produce high yields.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company